Phase II Study of Modified Carboplatin Plus Weekly Nab‐Paclitaxel in Elderly Patients with Non‐Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301

Conclusion.Modified CBDCA plus weekly nab‐PTX demonstrated significant efficacy and acceptable toxicities in elderly patients with advanced NSCLC.

Source: The Oncologist - June 13, 2017 Category: Cancer & Oncology Authors: Eisaku Miyauchi, Akira Inoue, Kazuhiro Usui, Shunichi Sugawara, Makoto Maemondo, Heisuke Saito, Yuka Fujita, Terufumi Kato, Toshiro Suzuki, Toshiyuki Harada, Hiroshi Watanabe, Taku Nakagawa, Masakazu Ichinose Tags: Lung Cancer, Chinese Edition, Clinical Trial Results Source Type: research